MX2020005471A - Compuestos para el tratamiento de trastornos neuromusculares. - Google Patents

Compuestos para el tratamiento de trastornos neuromusculares.

Info

Publication number
MX2020005471A
MX2020005471A MX2020005471A MX2020005471A MX2020005471A MX 2020005471 A MX2020005471 A MX 2020005471A MX 2020005471 A MX2020005471 A MX 2020005471A MX 2020005471 A MX2020005471 A MX 2020005471A MX 2020005471 A MX2020005471 A MX 2020005471A
Authority
MX
Mexico
Prior art keywords
treatment
neuromuscular disorders
phenoxy acids
phenoxy
acids
Prior art date
Application number
MX2020005471A
Other languages
English (en)
Inventor
Neerja Saraswat
Olesen Claus Elsborg
Pedersen Thomas Holm
Lars J S Knutsen
Nicholas Kelly
Marc Labelle
Paul Brian Little
Cooper Martin E
Dastagiri Dudekula
Rafiq A Taj
Original Assignee
Nmd Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nmd Pharma As filed Critical Nmd Pharma As
Publication of MX2020005471A publication Critical patent/MX2020005471A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/37—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos adecuados para tratar, mejorar y/o prevenir trastornos neuromusculares, incluyendo la reversión del bloqueo neuromuscular inducido por fármacos. Los compuestos como se definen en el presente documento inhiben preferiblemente el canal iónico ClC-1.
MX2020005471A 2017-12-14 2018-12-14 Compuestos para el tratamiento de trastornos neuromusculares. MX2020005471A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762598959P 2017-12-14 2017-12-14
EP18151651 2018-01-15
PCT/EP2018/084988 WO2019115780A1 (en) 2017-12-14 2018-12-14 Phenoxy acids for the treatment of neuromuscular disorders

Publications (1)

Publication Number Publication Date
MX2020005471A true MX2020005471A (es) 2020-08-27

Family

ID=64664308

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005471A MX2020005471A (es) 2017-12-14 2018-12-14 Compuestos para el tratamiento de trastornos neuromusculares.

Country Status (10)

Country Link
EP (1) EP3723746B1 (es)
JP (1) JP7287607B6 (es)
CN (1) CN111491628B (es)
AU (1) AU2018383005B2 (es)
CA (1) CA3085227A1 (es)
DK (1) DK3723746T3 (es)
ES (1) ES2911895T3 (es)
MX (1) MX2020005471A (es)
TW (1) TW201927738A (es)
WO (1) WO2019115780A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113072420B (zh) * 2021-02-23 2022-05-20 中山大学 一类2-芳基取代的偕二氟环丁烷类化合物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301009D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
GB0409921D0 (en) 2004-05-04 2004-06-09 Novartis Ag Organic compounds
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
EA201001224A1 (ru) * 2008-02-04 2011-08-30 Цитокинетикс, Инкорпорейтед Химические соединения, композиции и способы их использования
RU2015131314A (ru) * 2013-01-18 2017-02-27 Ф. Хоффманн-Ля Рош Аг 3-замещенные пиразолы и их применение в качестве ингибиторов dlk
ES2879826T3 (es) * 2015-06-15 2021-11-23 Nmd Pharma As Compuestos para su uso en el tratamiento de trastornos neuromusculares

Also Published As

Publication number Publication date
TW201927738A (zh) 2019-07-16
JP7287607B6 (ja) 2024-02-19
DK3723746T3 (da) 2022-05-23
ES2911895T3 (es) 2022-05-23
EP3723746B1 (en) 2022-02-23
JP2021506787A (ja) 2021-02-22
AU2018383005A1 (en) 2020-07-09
AU2018383005B2 (en) 2024-04-04
CN111491628B (zh) 2023-10-13
CN111491628A (zh) 2020-08-04
WO2019115780A1 (en) 2019-06-20
JP7287607B2 (ja) 2023-06-06
EP3723746A1 (en) 2020-10-21
CA3085227A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
MX2017016424A (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares.
PH12016501600A1 (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
EA201991862A1 (ru) Композиции и способы, предназначенные для лечения гемоглобинопатий
MX2019012818A (es) Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
PH12017500829A1 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease
MX2020005545A (es) Compuestos para el tratamiento de trastornos neuromusculares.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2017012730A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido) para el tratamiento de cancer.
MX2018012655A (es) Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.
EP3598980A3 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
PH12018502337A1 (en) Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions
MY195743A (en) Isoxazole Hydroxamic Acid Compounds as LPXC Inhibitors
MX2018008321A (es) Tratamiento de tumores ocasionados por disfuncion metabolica.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
PH12020550023A1 (en) Compositions for treating stress-related disorders
MX2017017171A (es) Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2024007360A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX2020005398A (es) Compuestos para el tratamiento de trastornos neuromusculares.
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
MX2019006940A (es) Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.
MX2020005471A (es) Compuestos para el tratamiento de trastornos neuromusculares.
SA521431094B1 (ar) مركبات علاج الاضطرابات العصبية والعضلية